X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PH80 is a first-in-class, rapid-onset product candidate, designed to be used in a manner analogous to a rescue inhaler for acute management of the symptoms of premenstrual dysphoric disorder.
Lead Product(s): PH80
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: PH80
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: VistaGen Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
Through the acquisition, Vistagen owns all intellectual property rights to PH94B (aloradine), in Phase 3 development for SAD and Phase 2 development for AjDA, and PH10, in clinical development for MDD, as well as three additional candidates in earlier stages of development.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Product Name: PH94B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: VistaGen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 02, 2023
Details:
PH94B (aloradine) is a first-in-class synthetic investigational neurosteroid developed from proprietary compounds called pherines. With its novel MOA, PH94B is a nasal spray designed to achieve rapid-onset anti-anxiety, or anxiolytic, effects.
Lead Product(s): Fasedienol
Therapeutic Area: Psychiatry/Psychology Product Name: PH94B
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: VistaGen Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
